Shares of CureVac N.V. (CVAC) are rising more than 14% Friday morning after the company announced positive preliminary data from the early-stage studies of COVID-19 and Flu vaccine candidates.
Results from the Phase 1 study showed that the company’s Covid-19 vaccine candidate CV0501, successfully boosted antibody titers against BA.1 and the wild type variants, and was generally well tolerated across all tested dose groups.
Flu vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain, even at lowest dose, the company said.
CureVac plans to advance these vaccine candidates to the next stage of study in this year.
CVAC is at $7.29 currently. It has traded in the range of $5.63-$31.84 in the last 1 year.
Source: Read Full Article
-
RXO Adds 8% In Morning Trade As Earnings Beat The Street View
-
Can Next Bitcoin Halving Push BTC Price To $148,000 By July 2025? Pantera Capital Thinks So
-
Bitwise CIO Foresees Bitcoin's Record Highs and Growing Investor Interest
-
BullFrog AI Surges Following License Agreement With Johns Hopkins University
-
Cryptos Weaken Amidst Worries Over SEC, Fed Moves